Back to search

Democritus University of Thrace (DUTH)

Μεσοπρόθεσμα και μακροπρόθεσμα αποτελέσματα από τη χρήση του ενδομοσχεύματος Endurant στην ενδοαυλική αντιμετώπιση των ανευρυσμάτων της κοιλιακής αορτής

Abstract

dc:description

Objectives: Durability after endovascular aortic aneurysm repair (EVAR) is con-sidered an on-going topic of investigation and was always questionable for all en-dografts (EGs) in terms of effective prevention of aneurysm related death, type I endoleaks and re-interventions. This skepticism remains also for the EndurantΤΜ device since few studies reported long-term outcomes at 5 years, although en-couraging. However, additional real-life experience and follow-up will need to as-sist these findings. Herein, we investigated the mid- and long-term (8 and 10 years) outcomes after EVAR, in real world practice using all the EndurantΤΜ EG versions. Material and Methods: 184 patients with infrarenal abdominal aortic aneurysms (AAA) ≥50mm in diameter treated with the EndurantΤΜ family EGs in a single vas-cular center were prospectively enrolled from January 2009 to December 2016. Follow-up was completed in March 31, 2022. Selection of EVAR using all the En-durantΤΜ EG generations was individualized according to aorto-iliac morphologic features, comorbidities, history of previous abdominal surgery and preference of the patient. In all stages of the study, this device was implanted not only in patients with regular anatomies but also in patients with challenging anatomical features and various aneurysm morphologies (real-world conditions). Kaplan-Meir esti-mates of long-term primary outcome measures including all-cause mortality, type I/III endoleak, any type of endoleak, aneurysm related secondary intervention, open surgical conversion (OSC) aneurysm rupture, aneurysm-related death and clinical success were performed. Secondary evaluations included adverse neck related events, limb thrombosis and sac enlargement > 5mm. Per protocol, sub-group comparison analysis was performed in 3 groups: patients treated within in-structions for muse (IFU) vs patients treated outside IFU, EVAR in aneurysms with wide necks (≥ 28mm) vs EVAR in those with necks 19-27 mm and EVAR with the Endurant I vs EVAR with the Endurant II vs EVAR with the Endurant IIs device. Results: The mean follow-up was 75.09 ± 37.9 months (range: 4.1-172 months). The median age of the study patients was 72.96 ± 7.03 years (range: 55-88 years). 177 patients were males (96.2%). Compliance with IFU was followed in 107 patients (58.2%). The three EndurantΤΜ versions used, including the two un-planned aortouniliac devices, resulted in overall primary and secondary technical success rate of 93.5% and 98.9% respectively. There were no intra-operative deaths from AAA rupture or device related primary OSC. Overall survival was 69.5% and 48% at 5 and 8 years respectively. Of the 102 all-cause deaths through to end of the study, seven (6.9%) were aneurysm related. Six of these post-implant deaths occurred in patients presented with aneurysm rupture from type Ia or/and type Ib endoleak. The remaining patient had EG infec-tion. At 3, 5, 8 and 10 years of observation, freedom from aneurysm rupture and OSC were 98.8% and 98%, 98.1% and 95.1%, 95% and 91.2%, and 89.4% and 85.7% respectively. Patients treated outside IFU had significantly higher risk of aneurysm rupture and OSC probability at 5 and 8 years [4.8% vs 2.6% and 10.7% vs 6.1% (p=0.037), 9.8% vs 4.3% and 15.6% vs 7.9% (p=0.014) respectively]. In a subgroup analysis, patients treated outside IFU (but having >1 hostile anatomical condition) had higher probability of aneurysm related death and aneurysm rupture than those treated within IFU at 5 years [18.7% vs 2.6% (p=0.039) and 16.4% vs 2.6% (p=0.008) respectively]. At 3, 5, 8 and 10 years, estimated freedom from type I/III endoleak probabilities was 98%, 93.6%, 85.6% and 82.3% respectively, while freedom from any type of endoleak probabilities was 88.4%, 83.4%, 74% and 70.9% respectively. Additionally, patients treated under IFU showed signifi-cantly better results regarding the occurrence of type I and/or III endoleak (free-dom at 5 and 8 years: 96.9% vs 84.9% and 90.6% vs 70.9% respectively, p=0.0048). This statistical difference remained when type Ia endoleak or endoleak of any type was considered independently [type Ia endoleak: freedom at 5 and 8 years: 97.4% vs 91.5%, and 92.4% vs 79.6% respectively (p=0.0253), any endo-leak: freedom at 5, 8 and 10 years: 88.4 vs 74.8%, 81.2 vs 59.8% and 79.8% vs 50.4% respectively (p=0.0163)]. Only two migrations at the level of the proximal neck were recorded (1.1%), without endoleak. Occlusion of an endoleg was ob-served in nine patients (4.9%), with four of them occured within the first year. Overall re-intervention rate was 17.4%. Freedom from aneurysm-related second-ary intervention probabilities at 3, 5 and 10 years was 94.3%, 89.8%, 76.7% and 72% respectively. Patients treated within outside IFU had higher chance of inter-ventions compared to in-IFU patients [freedom at 3, 5 and 8 years: 95.1% vs 92.5%, 93.3% vs 82.8% and 83.2% vs 63.7% respectively (p=0.0121)]. Estimated freedom from neck-related events over the 3, 5, 8 and 10 years was 98.9 ± 0.8%, 96.3 ± 1.6%, 90 ± 3.1% and 87.6 ± 3.9% respectively, with similar outcomes in patients in- or outside-IFU compliance. Increase in aneurysm sac diameter was observed in 12.5% of patients and also was not related to IFU status. Clinical suc-cess was 94.4%, 90%, 77.4% and 68.4% at 3, 5, 8 and 10 years respectively. Pa-tients treated within IFU had statistically better clinical success probabilities com-pared to patients treated outside-IFU [95.1% vs 92.5% at 3 years, 93.4% vs 82.8% at 5 years and 84.5% vs 63.5% at 8 years respectively (p=0.0076)]. Overall, the EndurantΤΜ version or the proximal EG diameter had no significant association with the chance of any complication or adverse event. Conclusions: The data confirmed the durability of the Endurant EG, achieving long-term outcomes in a real-world setting, comparable to that of similar larger bore devices, despite including a high proportion of patients treated off-label. Our promising 5-, 8- or 10-year outcomes suggest that EVAR with the Endurant EG has still several advantages against open repair. However, its positive performance must be interpreted with caution in patients treated off-label. In this cohort, some of EVAR advantages might be lost in the late future. Further similar studies are warranted.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Schoretsanitis, Nikolaos
  • Σχορετσανίτης, Νικόλαος

Subjects

dc:subject × 10

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52866

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Schoretsanitis, Nikolaos; Σχορετσανίτης, Νικόλαος. Μεσοπρόθεσμα και μακροπρόθεσμα αποτελέσματα από τη χρήση του ενδομοσχεύματος Endurant στην ενδοαυλική αντιμετώπιση των ανευρυσμάτων της κοιλιακής αορτής. Democritus University of Thrace (DUTH), 2022. http://hdl.handle.net/10442/hedi/52866